

Application Serial Number 10/579219  
Response to Office Action dated 01/11/2008

### **REMARKS**

Favorable reconsideration of this application is requested in view of the following remarks.

Drawings have been amended to include brief descriptions according to the Examiner's advice.

Claim 6 has been amended to include a limitation of the derivatives to specific optical isomers obtained from a natural raw material by a process in Example 1.0 at page 4 and Examples 9.0 from page 14, line 22 to page 15, line 23 of the specification and claim 7. This claim amendment also includes editorial revisions.

Claims 7, 8, 9, and 11 have been amended editorially.

Claims 10 and 12 have been amended following the Examiner's advice to comply with formalities; therefore, the objections to these claims are moot.

Claim 12, in addition, has been amended to limit diseases for which the present invention applies as supported by the specification at page 3, lines 24-27 of the specification and include a limitation to the optical isomers as shown in claim 6.

Claim 14 has been added as supported by substituents in claims 6 and 12 such as CO-CH<sub>2</sub>-Cl.

Claim 15 has been added as supported by the specification at page 3, lines 27-30; and page 13, lines 4-6 of the specification.

Claims 6-13 have been rejected under 35 U.S.C. 112, second paragraph, as being indefinite. Applicants respectfully traverse this rejection.

Application Serial Number 10/579219  
Response to Office Action dated 01/11/2008

Claim 6 now includes no prefix "ortho-" or "o-." Therefore, this rejection is moot.

Claim 7 requires to select appropriate halo compounds in order to obtain the target derivatives that have particular substituents of R1-R3 for Garcinol or R4 and R5 for Isogarcinol. Therefore, claim 7 and accordingly, also claims 8-11 are definite.

Claims 12 and 13 require that the diseases caused by the HAT be treated by the derivatives of Garcinol or Isogarcinol. Accordingly, claims 12 and 13 are not definite.

Therefore, the rejection of claims 6-13 should be withdrawn.


In view of the above, Applicants request reconsideration of the application in the form of a Notice of Allowance.

Respectfully submitted,



Hamre, Schumann, Mueller & Larson, P.C.  
P.O. Box 2902-902  
Minneapolis, Minnesota 55402  
(612) 455.3800

Dated: April 10, 2008

By   
Douglas P. Mueller  
Reg. No. 30,300

DPM/my/ad